<?xml version="1.0" encoding="UTF-8"?>
<p id="Par17">Other treatment option developments have focused on the use of antiviral drugs (such as favipiravir), type I interferon, anti-coagulant drugs, small interfering RNA, monoclonal antibodies and morpholino-oligomers [
 <xref ref-type="bibr" rid="CR76">76</xref>â€“
 <xref ref-type="bibr" rid="CR78">78</xref>]. A number of experimental vaccines have undergone safety and immunogenicity studies 
 <italic>in-vivo</italic> in various populations, although children have largely not been included in these studies. In phase 3 studies using a ring vaccination approach for post exposure prevention of EBV disease in potential contacts (&gt;18 years of age) a recombinant vesicular stomatitis virus based vaccine (rVSV-ZEBOV) showed very high efficacy [
 <xref ref-type="bibr" rid="CR79">79</xref>]. Social mobilization, patient isolation, infection control and use of personal protection equipment by health workers, contact tracing and monitoring for infection and safe burials are key traditional interventions in outbreaks.
</p>
